Date: Thu, 28 Mar 2024 16:17:07 +0000 (UTC)
Message-ID: <285122130.21.1711642627071@e18128075915>
Subject: Exported From Confluence
MIME-Version: 1.0
Content-Type: multipart/related;
boundary="----=_Part_20_1460884285.1711642627071"
------=_Part_20_1460884285.1711642627071
Content-Type: text/html; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Content-Location: file:///C:/exported.html
3/18/2024: Release v1.42.1.4
- Fixes a COVID-19 dose numbering issue to support incrementing of dose n=
umber for patients who did not complete a < 5 years series prior to 9/12=
/2023 and are continuing in a < 5 years series.
- Clarification to a COVID-19 Sept 2023 COVID-19 Series (>=3D 5 y=
ears) series special rule and corresponding logic update to address an exce=
ption related to handling CVX 313 in the >=3D 5 years series.
- Extends the "start" date for COVID-19 vaccine from 12/01/2020 to 1/01/1=
970 to prevent COVID-19 shots administered prior to 12/01/2020 from being a=
ssigned to the "Other" vaccine group.
3/07/2024: Rel=
ease v1.42.1.3
- Fixes an issue discovered in v1.42.1.2. In certain situations, some historical COVID doses prior to September 12, 2023 were bein=
g evaluated as Accepted rather than Valid. This release fixes this issue.=
li>
3/05/2024: Release v1=
.42.1.2
- Fixes an issue discovered in v1.42.1 where some shots in the COVID-19 &=
gt;=3D 5yr series were incorrectly being marked as Invalid.
3/01/2024: Release v1.4=
2.1
COVID-19 - September 2023 Onwards
COVID-19 Vaccine Group Rule Sets
- COVID-19 shots administered before 9/12/2023 are evaluated according to=
the logic specified in the COVID-19 Vaccine Group - Prior to September 12, 2023 wiki=
. Shots administered on or after 9/12/2023 are evaluated according to the l=
ogic specified in the new COVID-19 Vaccine Group - September 2023 Onwards wiki.
- The two COVID-19 Vaccine Group rule sets are designed to work with one =
another, with prior history (i.e., before 9/12/2023) influencing current re=
commendations, as per the ACIP and CDC guidelines.
11/03/2023: Release v1=
.41.1
Pneumococcal
- Added support for PCV20 (CVX 21=
6) use in children, with the following changes in the Pneumococcal Child Se=
ries:
- Lowered the absolute minimum ag=
e of CVX 216 from 18 years - 4 days to 6 weeks - 4 days.
- Incorporated CVX 216 as a valid=
CVX code per dose.
- The CVX 216 changes are in th=
e Pneumococcal Child Series only. In a future release, HLN will refine the lo=
gic for handling of CVX 216 administered between the ages of 6 and 19 years=
when intended for the adult series.
Note: There are no changes to =
the ICE Implementation Guide.
10/06/2023: Release v1=
.40.1
General Rule - Live Vaccine Interval
- Updated the live vaccine inte=
rval rule to allow for an absolute minimum interval of 24 days, instead of =
28 days, for live virus vaccines from the same vaccine group. Note, this is=
relevant for the following vaccine groups: H1N1, Influenza, MMR, Varicella=
, Zoster.
DTP
- Added logic to
recommend Tdap (CVX 115) when a patient is < 7 years, the series is not complete=
, and the recommendation date is at >=3D 7 years.
- Updated the recurring b=
ooster dose to recommend at the vaccine group level instead of a specific C=
VX, with a new recommendation reason code: ADMINISTER_TDAP_OR_TD.
Influenza
- Updated CVX names to better align with CDC CVX code descriptions=
.
- Minor rule edits to enhance rule clarity.
MMR
- Updated the dose 1 to dose 2 absolute minimum interval from 28 d=
ays to 24 days.
- Updated MMR deduplication/same day logic to evaluate an MMRV sho=
t first, followed by MMR, then other MMR vaccine group vaccines, in accorda=
nce with the Two Shots, Same Vaccine Group, Same Day Exception Rules for MM=
R.
- Addressed an issue where ICE incorrectly indicated a single anti=
gen or a double antigen vaccine as a valid dose of MMR for adults age 19 ye=
ars and older.
Varicella
- Updated the dose 1 to dose 2 absolute minimum interval from 28 d=
ays to 24 days for patients >=3D 13 years of age.
8/21/2023: Release v1.3=
9.2
COVID-19
- Pfizer Series: In certain cir=
cumstances (as follow), when recommending for the 2nd dose of the Pfizer se=
ries for patients >=3D 5 years of age and the 1st dose was administered =
with a monovalent vaccine and wi=
thin 8 weeks before 4/19/2023, ICE (1.39.1) incorrectly uses a 21 da=
y interval rather than an 8 week interval. We have updated the COVID-19 Vaccine Group page with these changes, which are noted in
blue in the Pfizer and Mixed Product Series interval tables near the bottom of=
the page.
- Novavax Series: If the Novava=
x Series was completed after 4/19/2023, ICE (1.39.1) was indicating that th=
e series was complete. Instead, the correct recommendation is a bivalent do=
se 8 weeks later.
7/20/2023: Release v1.3=
9.1
COVID-19
- Added support for a Pfizer bi=
valent booster dose for children aged 6 months through 4 years who previous=
ly completed a Pfizer-BioNTech 3-dose primary series. For children ages 6 m=
onths and older who have previously completed a 3-dose monovalent Pfizer-Bi=
oNTech primary series and have not received any bivalent vaccines, ICE reco=
mmends 1 bivalent Pfizer-BioNTech booster dose at least 2 months after comp=
letion of the monovalent primary series when the execution date is 3/17/202=
3 or later.
- Added support for bivalent va=
ccines in the primary series.
- Added support for the recomme=
ndation for patients aged 6 months and older to receive a bivalent COVID-19=
vaccine; this recommendation is applicable when the execution date is 4/19=
/2023 or later.
- Added a new recommendation re=
ason code: ADMINISTER_COVID19_BIVALENT_VACCINE.
- Fix to address a processing i=
ssue when two CVX 212 vaccines were administered to the same patient on the=
same day.
Influenza
- Updated wiki to reflect=
the 2023-2024 season. Note: there are no evaluation and forecasting change=
s for the 2023-2024 season.
- Added support for CVX 2=
31 (Influenza, Southern Hemisphere, high-dose, quadrivalent). Note: this CV=
X does not count toward immunity.
Pneumococcal
- Fix to the Adult Recommendation Rules supplemental text descript=
ive text when a patient is >=
=3D 19 years and < 65 years of age and the series is not complete. The d=
escriptive text now indicates patients who previously received a PCV13 shou=
ld receive PCV20 or PPSV23 (previously only PPSV23 was noted). =
3/17/2023: Release v1.3=
8.1
COVID-19
- COVID-19 CVX Code Updates: 230, 302, 518, 519, 520, 521 (new).
- Expanded bivalent vaccine recommendations for children ages 6 months th=
rough 5 years.
- Logic tweak: If the Janssen (CVX 212) and another COVID-19 FDA-approved=
shot are administered on the same day, evaluate the other shot fi=
rst.
DTP
- Added vaccines: (1) CVX 196 (Td); (2) CVX 195 (DT-IPV, Non-US)
Polio
- Added vaccines: CVX 195 (DT-IPV, Non-US)
Orthopoxvirus
- Tweak logic to not trigger live interval rule for shots administered af=
ter completion of the series. (Shots as Accepted / EXTRA_DOSE)
Hep B
- Added a bug fix to the ICE series selection rules; ICE was incorrectly =
selecting the Hep B 2-dose series, in some instances, when it should have s=
elected the Hep B 3-dose series.
Pneumococcal
- Supplemental text working change. Remove mention of Pfizer in the last =
sentence of one of the supplemental text descriptions.
12/12/2022: Release v1=
.37.2
COVID-19
- Incorrect evaluation of=
some shots due to malformed XML in the Mixed Product Series and series sel=
ection logic related to CVX 213.
Hep B
- When no shots are admin=
istered, incorrect conditional status for patients >=3D 19 year=
s of age. Conditional status should start at age >=3D 60 years.=
span>
12/7/2022: Release v1.3=
7.1
CVX Update:=
- Added CVX 198 (DTP-hepB-Hib Pentavalent=
Non-US)
COVID-19 Update:
- Added support for Novavax as a primary series option for ages 12 and ol=
der: new Novavax COVID-19 Series
- Added support for bivalent boosters f=
or ages 5 and older
- Add=
ed support for Novavax monovalent booster for adults ages 18 and older
- Added support for new vaccines: CVX 229, CVX 300, and CVX 301
- Updated the Pfizer COVID-19 Series
- additional valid CVX codes per dose: CVX 300, CVX 301
- indication of an invalid CVX code per dose: CVX 229
- indication of a latest recommended interval for dose 1 to dose 2: 8 wee=
ks
- additional series special rules
- Updated the Moderna COVID-19 Series
- additional series special rules
- Updated the Mixed Product COVID-19 Series
- additional valid CVX codes per dose: CVX 211, CVX 300, CVX 301
- indication of an invalid CVX code per dose: CVX 229
- additional series special rules
- removed Rule for CVX 218
- Updated General Rules
- Updated Series Completion Special Rules
- Moderna COVID-19 Series: Added logic based on execution date
- Pfizer COVID-19 Series or Mixed Product COVID-19 Series: Added logic ba=
sed on execution date
- COVID-19 vaccine series not authorized by the FDA, but authorized by th=
e WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but i=
s an active COVID-19 vaccine candidate as part of a U.S.-based clinical tri=
al of a COVID-19 vaccine: Added logic based on execution date
- Updated and added Booster Dose rules: Added recommendation and evaluati=
on rules for third booster dose
- Updated and added Additional Dose rules
Hepatitis B Update:
- Added support for universal recommendation of Hepatitis B for adults ag=
e 19 through 59 years: new Hepatitis B 3-dose Adult Series
- Modified the Hepatitis B 3-dose Child/Adult Series to be a Hepatitis B =
3-dose Child/Adolescent Series
Orthopoxvirus Update:
- Added new series selection rule: when two shots are administered on the=
same day, follow the Orthopoxvirus 2-dose Series, not the Orthopoxvirus 1-=
dose Series
Pneumococcal Update:=
- Added support for PCV15 as an=
option for pneumococcal conjugate v=
accination of persons age <19 years
- Fixed bug that, in certain circumstances, recommended an extra PPSV23 =
after the series had already been completed at >=3D 65 years
8/31/2022: Release v1.3=
6.1
Orthopoxvirus Vaccine Group =
- May 2022 Emergency Use Authorization (EUA) for Monkeypox (Optional):=
- The vaccine group can optionally be enabled or disabled.
- In the zipfile distribution, the Orthopoxvirus vaccine group is dis=
abled by default.. It can be enabled by removing the property value VA=
CCINE_GROUP_CONCEPT.860 from the vaccine_group_exclusions property=
in the ice.properties file. The vaccine_group_exclusions property=
is a way to omit vaccine groups from the forecast, comma-delimited.
- In the docker image distribution, the Orthopoxvirus vaccine group is enabled by default. It can be disabled by setting the VACCINE_GROUP_=
EXCLUSIONS environment variable with the value VACCINE_GROUP_CONCEPT.860.=
li>
- New vaccines: CVX codes 75, 105, 206
Pneumococcal Update:=
- Added new recommendation rule=
: "If the patient is < 65 years of age, received a valid dose in an Adul=
t Series at < 65 years old, and the series is not complete, recommend Co=
nditional/ HIGH_RISK".
7/25/2022: Release v1.3=
5.3
COVID-19 Update:
- Improved series selection handling to ensure that a series whi=
ch was completed earlier is always selected
- If CVX 213 (NOS) is administe=
red as the first dose, the recommended interval is 28 days, not 21 days
7/21/2022: Release v1.3=
5.2
COVID-19 Update:
- This release fixes an issue i=
dentified in yesterday's release (v1.35.1) which occasionally results in re=
quests to fail due to an error in the COVID-19 series implementation. Both =
the zipfile distribution and docker image have been updated with this lates=
t release.
7/20/2022: Release v1.3=
5.1
Pneumococcal Update:
- This release includes the following Pneumococcal updates:
- Updated Pneumococcal rules to accommodate changes to the Adult Schedule=
- Added support for new adult vaccines: CVX 215 (PCV15) and CVX 216 (PCV2=
0)
COVID-19 Update:
- This release includes the following COVID-19 updates:
- Updated booster dose logic to support recommendation of a 2nd booster d=
ose, when applicable
- Updated the schedule for patients 6 months and over, and added support =
for newer vaccines: CVX codes 219, 221, 227, 228, 512, 513, 514, 515, 516, =
517
Hep B Update:
- Added support for the CVX 220 (PreHevbrio) to the Hep B schedule
Additional Updates:
- A new endpoint to request the version of the service that is running: <=
em>http(s)://<host>:<port>/path/to/opencds-decision-support-ser=
vice/version
- Fix for occasional "getValidShotByDoseNumber()" error
2/1/2022: Release v1.34.=
1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Added additional support and logic in=
ICE to handle the following:
- Booster Dose Rules
- Updated booster dose recommended age to 12 years
- Updated booster dose recommended interval to 5 months after completion =
of mRNA vaccine primary series.
- Additional Dose Rules
- Added support for additional dose for immunocompromised persons aged 5+=
- COVID-19 Vaccines Not Authorized by FDA Rules
- Updated rules for Novavax (CVX 211) COVID-19 vaccine now that WHO has a=
pproved it for use under their EUL
- Updated rules to accommodate the fact that patients who have not comple=
ted all recommended doses of a COVID-19 vaccine series not authorized by FD=
A, but approved by WHO, do n=
ot need to restart a primary vaccination series in the United States. =
12/22/2021: Release v1=
.33.1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Added additional support and logic in=
ICE to handle the following:
- COVID-19 Booster Dose rules - Updated and added additional rules for pa=
tients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1=
-dose series, Pfizer COVID-1=
9 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized b=
y the FDA, but authorized by the WHO, or a COVID-19 vaccine series not auth=
orized by the FDA or WHO, but is an active COVID-19 vaccine candi=
date as part of a U.S.-based clinical trial of a COVID-19 vaccine.&nbs=
p;
- Booster Dose Minimum Age has =
been updated to 16 years to support new CDC recommendation that 16-17 year =
olds "may" receive a Pfizer booster.
- COVID-19 Additional Dose rules - Updated and added additional rules for=
patients who completed Pfizer 2-dose series, Moderna 2-dose series, J=
anssen 1-dose series, Pfizer=
COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not auth=
orized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series =
not authorized by the FDA or WHO, but is an active COVID-19 vacci=
ne candidate as part of a U.S.-based clinical trial of a COVID-19 vacc=
ine.
- New COVID-19 vaccine (CVX 217=
) - Added support and logic
- Note - CVX 217 is a new P=
fizer formulation for ages 12+ under EUA; can be used in the same way as CV=
X 208
- Pfizer 2-dose series
- Updated Absolute Minimum Intervals between Dose 1 and Dose 2=
span>
- Moderna 2-dose series =
span>
- Updated Absolute Minimum Inte=
rvals between Dose 1 and Dose 2
- Updated Absolute Minimum Age for Dose 1
- Updated Absolute Minimum Age =
for Dose 2
- Updated Minimum Age for Dose =
2
- Updated Routine Age for Dose =
2
- This release includes an impo=
rtant security update. We strongly recommend that users update to th=
is release as soon as possible.
12/13/2021: Release v1=
.32.2
- This release adds an important security update. We strongly recommend t=
hat users update to this release as soon as possible.
11/24/2021: Release v1=
.32.1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Added additional support and logic in=
ICE to handle the following:
- An updated Implementation Guide with the following new codes:
- CVX 218 - vaccine code for the COVID-19 Pfizer pediatric vaccine
- BOOSTER_DOSE - new recommendation reason code to indicate that the reco=
mmendation is for a booster dose.
- Note about upcoming ICE release (scheduled for December 2021)
- As always, HLN is actively mo=
nitoring all news and updates in regards to new and existing COVID-19 vacci=
nes. Currently, we are working on adding additional support and logic (base=
d on latest published guidance) in ICE to handle the following:
- Updates to Booster Dose rules
- Updates to Additional Dose rules
- Updated Absolute Minimum Intervals and Absolute Minimum Ages
10/25/2021: Release v1=
.31.1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Added additional support and logic in=
ICE to handle the following:
- Performance Improvement:
- On service start up, if the km.threads property configuration =
value is increased, ICE no longer requires additional memory to establish t=
he increased number of threads.
- Note about upcoming ICE release (tentatively scheduled for mid-November=
2021)
- As always, HLN is actively mo=
nitoring all news and updates in regards to new and existing COVID-19 vacci=
nes. Currently, we are working on adding additional support and logic (base=
d on latest published guidance) in ICE to handle the following:
- COVID-19 Booster Dose for Mod=
erna and Janssen Vaccines
9/21/2021: Release v1.3=
0.1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Added additional support and logic in=
ICE to handle the following:
- COVID-19 Additional Dose - a dose administered when the immune response=
to a standard primary vaccine series is likely not to be protective.
- Note - Alternatively, a =E2=80=9Cbooster=E2=80=9D dose of vaccine i=
s a dose administered to restore protection after the effectiveness of prot=
ection from the primary series has declined. Once FDA approval is granted a=
nd ACIP recommendations are published in regards to "booster" doses, ICE wi=
ll be updated accordingly; updates will likely be included in the next rele=
ase of ICE.
- COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO
- Note - The previous version of ICE, Version 1.29.1 supports the han=
dling of one COVID-19 vaccine that falls under this category - AstraZeneca =
COVID-19 vaccine (CVX 210).
- COVID-19 Vaccines Not Authorized by the FDA or WHO
- COVID-19 Vaccines Not Authori=
zed by the FDA or WHO, but is an active COVID-19 vaccine candidat=
e as part of a U.S.-based clinical trial of a COVID-19 vaccine<=
/li>
Live Virus Bug Fix:
- Fix bug where, in certain circumstances, ICE is incorrectly recommendin=
g Varicella or MMR 28 days later rather than on the same day.
5/14/2021: Release v1.2=
9.1
COVID-19 Update:
- This release includes the fol=
lowing COVID-19 updates:
- Updates have been made to exp=
and age ranges down to >=3D12 years old for the Pfizer COVID-19 Vaccine =
(CVX 208).
- For patients with no prior doses of COVID-19 vaccine, updated =
recommendations to recommend COVID-19 to patients >=3D 12 years old.&nbs=
p;
- Note - ICE previously had a conditional recommendation for patients=
with no prior doses of COVID-19 vaccine.
- Support has been added to han=
dle AstraZeneca COVID-19 vaccine (CVX 210) shots reported on the patient re=
cord.
- As of now, the AstraZeneca CO=
VID-19 vaccine has not yet been FDA approved in the U.S. , but is approved =
by the WHO. See COVID-19 Vaccine Group - Prior to September 12, 2023 page for details=
.
- When the FDA approves the Ast=
raZeneca COVID-19 vaccine (C=
VX 210) for use in the U.S., ICE will be updated as necessary. =
- In addition to the above updates, added evaluation reason code VACCINE_NOT_APPROVED_IN_US to the ICE Implementation Guide. =
- Note: This is implementat=
ion of COVID-19 Vaccine Group in ICE based on interim recommendations from =
ACIP. As additional guidelines from ACIP are published and/or vaccine=
s become available, the COVID-19 logic in ICE will be updated.<=
/li>
Influenza Update:
- Influenza 2021-2022 Season ru=
les remain unchanged from last season. ICE has been updated to reflect that=
.
3/15/2021: Release v1.28.3
COVID-19 Bug Fix:
- Fixes a bug that resulted in the earliest date to be set to 4 days earl=
ier than the recommended due date. Earliest date should be calculated as fo=
llows:
3/12/2021: Release v1.28.2
COVID-19 Bug Fix:
- Fixes a bug that resulted in, under certain circumstances, some COVID s=
hots administered on the same day to be incorrectly evaluated.
3/3/2021: Release v1.28.1
COVID-19 Update:
- This implementation of COVID-=
19 Vaccine Group in ICE based on interim recommendations from ACIP. A=
s additional guidelines from ACIP are published and/or vaccines become avai=
lable, the COVID-19 logic in ICE will be updated.
- This release has added suppor=
t for the Janssen COVID-19 Vaccine (CVX 212). =
General Rules:
- Updated the ICE General Rule =
"Select Adjuvant Product Interval Rule" to remove the absolute minimum inte=
rval of 24 days between the following vaccine codes. The recommended interv=
al of 28 days between the following vaccines remains.
- CVX 189 (Hep B)
- CVX 187 (Zoster)
- CVX 168 (Influenza)
- CVX 205 (Influenza)
12/23/2020: Release v1=
.27.1
COVID-19 Update:
- This is implementation of COV=
ID-19 Vaccine Group in ICE based on interim recommendations from ACIP. =
; As additional guidelines from ACIP are published and/or vaccines become a=
vailable, the COVID-19 logic in ICE will be updated.
- This release includes support=
for the Pfizer COVID-19 vaccine (CVX 208), Moderna COVID-19 vaccine (CVX 2=
07), and COVID-19, Unspecified Formulation (CVX 213).
- In addition to the above CVX codes, added recommendation reason code&nb=
sp;BASED_ON_VAC_AVAIL_AND_PRIORITY_RECS t=
o the ICE Implementation Guide.
- The updated ICE Implementation Guide documents these codes.=
A version of th=
is same guide with the changes since 1.24.1 highlighted and =
a Google Sh=
eet with the same ICE codes are also available as an added convenience.
12/15/2020: Release v1=
.26.2
COVID-19 Bug Fix:
- Bug fix for COVID-19 introduc=
ed in Version 1.26.1. Users who installed Version 1.26.1 should update to t=
his release as soon as possible.
- Note: The subsequent release,=
soon after, will likely add support for the Moderna vaccine.
12/14/2020: Release v1=
.26.1
COVID-19 Update:
- This is a pre-release im=
plementation of COVID-19 Vaccine Group in ICE. We are implementing CO=
VID-19 in stages, as more information and ACIP guidelines are published. =
span>
- This first pre-release will c=
ontain support for the Pfizer vaccine only.
- Note: The subsequent release,=
soon after, will likely add support for the Moderna vaccine.
12/1/2020: Release v1.2=
5.1
Meningococcal ACWY Update
Hep B Update
Hep A Update
HPV Update
MMR Update
11/10/2020: Release v1=
.24.2
Fixes to v1.24.1
- MMR: for patients >=3D 19 yrs of age, 1.24.1 incorrectly marked the =
2nd shot Accepted when it was Valid.
- Display: ICE was identifying itself as "ICE_1.23.1" in the output. This=
version of ICE correctly outputs version "ICE_1.24.2"
11/6/2020:=
Release v1.24=
.1
Software Update
- The output_supplemental_text option is now enabled by default in the downloadable distribution, but can be disabled by sett=
ing this option to "N" in the ice.properties file. Supplemental text is cur=
rently returned by some DTP and Pneumococcal rules when evaluating shots or=
in the recommendation. The ICE Implementation Guide describes this feature=
.
- Upgraded to the latest version of drools.
DTP Update
- Updated rules in regards to the recent ACIP recommendations indicating&=
nbsp;booster doses of either Td or Tdap should be administered every 10 yea=
rs throughout life. The recurring booster dose will now be recommended at the vaccine=
group level, rather than at the CVX level.
- Updated rules to evaluate Td =
(CVX 09, 113, 138, 139), administered in the DTP 5-dose series:
- If administered below the CVX=
Absolute Minimum Age (< 7 years - 4 days), evaluate as Invalid/&nb=
sp;BELOW_MINIMUM_AGE_VACCINE.
- If administered above or equa=
l to the CVX Absolute Minimum Age (>=3D 7 years - 4 days), evaluate as V=
alid and return evaluation reason code SUPPLEMENTAL_TEXT and Descripti=
ve Text: "Pertussis is needed to compl=
ete the series.
- Updated rules to return evalu=
ation reason code SUPPLEMENTAL_TEXT and Descriptive Text when DT (CVX 28) i=
s administered.
- Updated DTP 5-dose Series Exc=
eption Rule "Series Complete with 4 Doses" to include additional criteria r=
equiring an interval between dose 3 and 4 of >=3D 6 months - 4 days=
.
- Fixed a bug where the Ad=
olescent Tdap absolute minimum interval of 0 days was not being applied (fo=
r accepted/extra dose non-pertussis shot to target Adolescent Tdap).=
Varicella Update
Hib Update
MMR Update
- Updated rules to include a MMR Series special rule that allows for adul=
ts to complete the MMR series with 1 dose to align with ACIP.
General Rule Update
- Added a new general rule wher=
e the "Earliest, recommended, and past due dates must be on or after the la=
st shot given."
9/13/2020: R=
elease v1.23.1
Influenza Update
-
Add=
ed support for the following CVX codes: 194, 197, 200, 201, 202, 205=
- Updated rules to indicate tha=
t the schedule for Influenza season 2020-2021 remains unchanged from the pr=
evious season.
General Update
- Updated existing general rule=
"Select Adjuvant Product Interval" to add CVX 205 to list of vaccine codes=
where this rule applies.
- Updated the evaluation code "ABOVE_MAX_AGE_VACCINE" to "ABOVE_MAXIMUM_A=
GE_VACCINE".
2/12/2020: R=
elease v1.22.1
Pneumococcal Update
- Updated Pneumococcal rules as per the June 2019 ACIP Vote:
- PCV13 vaccination is no longe=
r routinely recommended for all adults aged =E2=89=A565 years. Instead, sha=
red clinical decision-making for PCV13 use is recommended for persons aged =
=E2=89=A565 years who do not have an immu=
nocompromised condition, CSF leak, or cochlear implant and who =
have not previously received PCV13.
- ACIP continues to recommend that all adults aged =E2=89=A565 y=
ears receive 1 dose of PPSV23. A single dose of PPSV23 is recommended for r=
outine use among all adults aged =E2=89=A565 years.
- Reference MMWR, November 22, 201=
9, Vol. 68, No. 46 for additional information.
DTP Update
- Fixes a bug, where in certain rare circumstances, for patients >=3D =
7 years, ICE was not applying the minimum age override of 7 years to calcul=
ate the earliest date.
Influenza=
Update
- Fixes a bug, where in certain circumstances, incorrect results may have=
been returned if ICE was not running on a server with its clock s=
et to an east coast timezone. (Shots may incorrectly have been reported as =
OUTSIDE_FLU_SEASON when they were not.)
General Update
- Version of ICE Output in Response - ICE now o=
utputs the version of the service in the response. See Version Number in the Response Message for detail=
s.
- Month-Based Forecast Calculation - ICE General Rules r=
egarding the calculation of month-based forecasts have been updated to alig=
n with CDSi's method of calculating month-based forecasts. According t=
o CDC: Guidance in CDSi Logic Specification, General Date Rules, CALCDT-5: =
A computed date which is not a real date must be moved forward to first day=
of the next month.
- The ICE General Rules that have been updated are:
- How to Calculate Recommended Age Using Calendar Months:
- Original - When calculating recommended age u=
sing calendar months, if the date of birth anniversary day does not exist (=
because the anniversary month has fewer than 31 days), use the last day of =
the anniversary month. For example, if a patient was born on 12/31/2012 and=
dose 1 is recommended at 4 months, the due date would be 4/30/2013.
- New=
- When calculating recommended age using calendar months, if the date of b=
irth anniversary day does not exist (because the anniversary month has fewe=
r than 31 days), use the first day of the next month. For example, if a pat=
ient was born on 12/31/2012 and dose 1 is recommended at 4 months, the due =
date would be 5/1/2013.
- How to Calculate Recommended Interval Using Calendar Months:
- Original - When calculating recommended inter=
val using calendar months, if the anniversary day does not exist (because t=
he anniversary month has fewer than 31 days), use the last day of the anniv=
ersary month.
- New=
- When calculating recommended interval using calendar months, if the anni=
versary day does not exist (because the anniversary month has fewer than 31=
days), use the first day of the next month.
- Dose Override Feature - New Opt=
ional Feature. If this option is set to "Y" in the ice.properties file=
, the Dose Override Feature enables a client application to manually f=
lag any administered shot as Invalid, Valid, or Accepted for any request it=
sends to the ICE service.
- This gives the client application the ability to =E2=80=9Cforce=E2=80=
=9D ICE to evaluate the shot as denoted by the client application.
- In addition to the evaluation status (i.e. - =E2=80=9CInvalid=E2=80=9D,=
=E2=80=9CValid=E2=80=9D or =E2=80=9CAccepted=E2=80=9D), the client applica=
tion may provide one or more evaluation reason codes with the administered =
shot. The evaluation reason code(s) must be a code in the Evaluation Reason=
Code code system listed in the ICE Implementation Guide and on the Wiki.=
li>
-
When an evaluation is provided by the client application, ICE will simpl=
y skip the evaluation of the shot and return the same data in the response =
that was provided to it in the request. In addition, ICE will take into acc=
ount the evaluation status of the=
manually evaluated shot when evaluating other shots that may be impacted b=
y it (e.g. - live virus interval or other vaccines that may be impacted).=
=E2=80=9D
- Output Supplemental T=
ext Feature =
- New Optional Feature. If this option is =
set to "Y" in the ice.properties file, ICE may return supplemental tex=
t in the response. This is currently being used by the Pneumococcal Vaccine=
Group for shared clinical decision making in the recommendation (interpret=
ation element). The Pneumococcal Vaccine Group=
rules page specifies the circumstances in which this occurs. (If the o=
ption is disabled, Pneumococcal will still operate correctly; applications =
simply won't benefit from additional text which may be displayed on the scr=
een.)
- "361 days" to "1 year=
- 4 days" - Updated all instances of "361 days" to "1 year - 4 da=
ys" in the ICE3 rules to align with CDSi. This update affects the following=
vaccine groups: DTP, Hep A, Hib, MMR, Pneumococcal, and Varicella.<=
/li>
10/15/2019: Release v1.21.1
HPV Update
- Updated HPV rules as per the June 2019 ACIP Vote:
- Harmonized recommendation for=
catch-up vaccination for males and females through age 26 years who are no=
t adequately vaccinated.
- Recommends vaccination based on shared clinical decision making for ind=
ividuals aged 27 through 45 years who are not adequately vaccinated. <=
/li>
General Update
- A d=
uplicate shot/same day fix whereby, in certain circumstances, a non-combina=
tion shot might be selected instead of the combination shot.<=
/li>
- Slight change to the way the dose num=
ber included in the vMR output is determined. The dose number represents th=
e targeted number of the dose in the series, whether the dose is valid or i=
nvalid (so, for instance, both a "valid" second dose following an invalid s=
econd dose will have dose number 2 indicated). However, if the patient has =
passed the eligible last date for a particular dose (e.g., Hib, Pn=
eumococcal) and receives a subsequent dose, the dose number of that subsequ=
ent dose will indicate the count of actual doses received and will not cons=
ider the earlier dose that was missed which cannot now be administered.
8/28/2019: Release v1.20.1
DTP Update
- Updated the DTP Adolescent Tdap Recommendation and Evaluation rules as =
per the new Tdap guidance included in the 2019 CDC Immunization Schedule
- Added a DTP 3-dose series exception rule requiring that in order for a =
primary series to be complete via the DTP 3-dose series, at least one of th=
e doses given must be a pertussis-containing dose
5/31/2019: Release v1.17.1
HPV Update
- Updates to HPV 3-dose series to align with CDSi
- Updated Recommended Interval between Dose 1 and 2 from 1 month to 4 wee=
ks
- Updated Absolute Minimum Interval between Dose 1 and 3 from 112 days to=
5 months - 4 days
DTP Update
- Updated the DTP 3-dose series Absolut=
e Minimum Interval between Dose 2 and 3 from 164 days to 6 months - 4 days =
to align with CDSi.
- Updated Adolescent Tdap Exception A R=
ule to "The patient&nb=
sp;DOES NOT have a dose of pertussis =
span>vaccine at >=3D=
4 years - 4 days."
Zoster Update
- Added rule "Recommended Interval After Adult Varicella (CVX 21) Doses"
- If patient is administered adult varicella (CVX 21) doses, the min=
imum interval and recommended interval between the adult varicella (CVX 21)=
doses to Zoster is 8 weeks.
- Example:
- Varicella (CVX 21) at 50 years, 1 month.
- Varicella (CVX 21) at 50 years, 3 months.
- Recommend Zoster (CVX 187) at Varicella Dose 2 + recommended interval (=
8 weeks)
Pneumococcal Update
- Fixes a bug in the Adult Series where (under certain rare circumstances=
) the PPSV to PPSV 5 year recommended interval is not being applied when th=
ere is a valid PCV shot in between the PPSV shots.
General - Same Day Shots Update
- Updated and improved the handling of =
shots administered on the same day.
3/7/2019: Release v1.16.1
General
- Please refer to the March 7 News entry for general informat=
ion and suggestions related to this release.
Pneumococcal Update
- Updated recommendation rule to distin=
guish between patients >=3D5 years old who have completed the childhood =
Pneumococcal series and patients who have not. The updated rule states:
- "If a patient is >=3D=
5 years (or will be >=3D 5 years at the recommended due date)=
and < 65 years, and they have completed the Child Series, then the Re=
commendation is Conditional and the reason code is COMPLETE_HIGH_RISK; otherwise the Recommendation is=
Conditional =
;and the reason cod=
e is HIGH_RISK."=
Polio Update
- Updated Series complete with =
3-doses rule to include the minimum interval =3D 6 months and absolute mini=
mum interval =3D 6 months - 4 days.
Meningococcal B Update
- Updated recommendation reason=
code returned if no doses are on record and the patient is >=3D 24=
years old, then the Recommendation is Conditional and the reason code is&n=
bsp;HIGH_RISK.
Rotavirus Update
- Updated recommendation reason=
code returned if the patient is >=3D 105 days old (i.e., >=3D 15 wee=
ks old) and has not received any doses of rotavirus vaccine, then the Recom=
mendation is Not Recommended and the reason code is TOO_OLD_TO_INITIAT=
E (new recommendation code).
DTP Update
- Added an update to the Six by Seven rule to explicitly state that dupli=
cate shots (or same day shots) do not count towards this rule.
Hib Update
- Fixes a bug in the duplicate =
shots (or same day shots) logic that resulted (under certain rare circumsta=
nces) in shots being evaluated incorrectly.
2/1/2019: Release v1.15.=
1
Hep B Update
- Addition of a new 2-dose Adult series to support HEPLISAV-B
- Fixes a bug in the Hep B 3-dose Child/Adult series that resulted in (un=
der certain circumstances) the incorrect minimum interval being applied in =
calculating the earliest date.
Men B Update
- Updates to Trumenba 3-dose series to align with CDSi Men B clarificatio=
ns/updates
- Updated Routine Age for Dose 2 from 10 years, 2 months to N/A
- Updated Routine Age for Dose 3 from 10 years, 6 months to N/A
- Updated Absolute Minimum Interval between Dose 1 and 2 from 2 months - =
4 days to 4 weeks - 4 days.
- Updated Recommended Interval between Dose 1 and 2 from 2 months to 4 we=
eks.
- Updated Absolute Minimum Interval between Dose 1 and Dose 3 from 6 mont=
hs - 4 days to 0 days.
HPV Update
- Updated Recommended Interval between Dose 1 and Dose 2 in HPV 3-dose se=
ries from 2 months to 1 months to align with CDSi
Influenza Update
- Updated Vaccine Allowable Age Ranges for select Influenza vaccines
- Changed Flu Season Start Date from Aug 1 to July 1 (for this year and p=
rior years)
Polio Update
- Updated Series Complete with 3 doses rule
- Updated Dose 4 grandfathered date of 8/7/2010 to 8/7/2009 to further al=
ign with CDSi
DTP Update
- Fixes a bug in the 5-dose Series Exception Rule "Series complete with 3=
Doses" that resulted in (under certain circumstances) the rule not being a=
pplied.
General Rule Update
- Added a new General Rule "Select Adjuvant Product Interval" which state=
s:
- The following vaccine codes must be administered with an absolute minim=
um interval of 24 days; otherwise the vaccine that does not meet the absolu=
te minimum interval will be evaluated as Invalid with a reason code of =E2=
=80=9CSELECT_ADJUVANT_PRODUCT_INTERVAL=E2=80=9D. The recommended interval i=
s 28 days.
- CVX 189 (Hep B)
- CVX 187 (Zoster)
- CVX 168 (Influenza)
8/10/2018: Release v1.1=
4.1
Overdue Date/Earli=
est Date
- Completed Overdue Date/Earlie=
st Date Feature. (Functionality Added for Remaining Vaccine Groups (Hep B, =
DTP, HPV))
6/17/2018: Release v1.1=
3.1
Pneumococcal Updat=
e
-
Added an exception rule to the 4-dose Child Series: When patients are &g=
t;=3D7 months and < 12 months at the time of execution and have received=
1 dose prior to 7 months old, 2 additional doses are indicated at >=3D7=
months old.
-
Updated Accepted reason code: VACCINE_NOT_ALLOWED_FOR_THIS_DOSE to VACCI=
NE_NOT_PART_OF_THIS_SERIES.
Overdue Date/Earli=
est Date
- Overdue Date/Earliest Date Fu=
nctionality Added for Select Vaccine Groups (Pneumococcal, Hib)
4/13/2018: Release v1.1=
2.1
Zoster Update=
- Support for the new Zoster va=
ccine (Shingrix - CVX 187) has been added to ICE.
MMR Update
- Support for the MMR 3rd dose =
high risk recommendation has been added to ICE.
Hep B Update<=
/strong>
- Support for the new Hep B vac=
cine (HEPLISAV-B - CVX 189) has been added to ICE to mark administration of=
CVX 189 vaccine as "Not Evaluated" with reason code "VACCINE_NOT_SUPPORTED=
". (The ICE team will work on a future release with further support f=
or CVX 189 once more information is provided by national guidance sources s=
uch as ACIP, CDC, etc...)
Shots Administered=
"before" the Patient's DOB
- Improved handling of shots marked as =
administered before the patient's date of birth.
Overdue Date/Earli=
est Date
- Overdue Date/Earliest Date Fu=
nctionality Added for Select Vaccine Groups (Hep A, MMR, Zoster)
3/9/2018: Release v1.11.1
Overdue Date/Earli=
est Date
- Overdue Date/Earliest Date Fu=
nctionality Added for Select Vaccine Groups (Polio, Meningococcal ACWY, Rot=
avirus, Varicella)
General Rule Updat=
e
- Fixes a bug that resulted in =
the General Rule "Shots Administered Below Series Absolute Minimum Age for =
Dose 1" not triggering when there are 2 or more invalid shots given below t=
he absolute minimum age for Dose 1.
12/19/2017: Release v1.10.1.0
DTP Update
- Fixes a bug that resulted in =
(under certain circumstances) the 4th dose to be evaluated as Accepted rath=
er than Valid.
Influenza Update=
em>
- Fixes a bug that resulted in =
a 2nd dose being recommended during the 2017-2018 season, when only 1 dose =
is needed.
11/20/2017: Release v1.9.2.0
Hib/Meningococcal =
ACWY Update
- Fixes a bug that resulted in =
the vaccine Meningococcal C/Y-HIB PRP (CVX 148) to be incorrectly evaluated=
as a part of the Meningococcal vaccine group (in addition to the Hib vacci=
ne group). Version 1.9.2.0 correctly evaluates this vaccine as a part of th=
e Hib vaccine group only.
10/6/2017: Release v1.9.1.0
Meningococcal B Up=
dates:
Hepatitis B Updates
- Updated and expanded upon the existing "Enough is Enough" rule:
- Original: If the patient gets 3 or more shots prior to age 164 d=
ays and has a dose 2, there is no minimum interval between the next-to-last=
shot and dose 3 (the final dose) but the patient must a.) m=
eet the minimum interval between dose 2 and the final dose (52 days) and b.=
) meet the minimum age for the final dose in the series (164 days).
- Updated: If a patient receives target dose 3 that is invali=
d (e.g. due to minimum interval violation or minimum age violation), t=
here is no minimum interval between the next-to-last shot (invalid shot) an=
d dose 3 (the final dose), but the patient must a.) mee=
t the minimum interval between dose 2 and the final dose (52 days), b.) mee=
t the minimum age for the final dose in the series (164 days), and c.) meet=
the minimum interval between dose 1 and dose 3 of 16 weeks.
HPV Updates:
- Fix to the HPV Series Selection Rules logic where if the HPV 3-dose ser=
ies is triggered and applied, it cannot switch back to applying the HPV 2-d=
ose series.
DTP Updates:
- Support for CVX 170 has been added to DTP Vaccine Group. Note - This is=
a non-US vaccine.
Hib Updates:
- Support for CVX 170 has been added to Hib Vaccine Group. Note - Th=
is is a non-US vaccine.
8/2/2017: Release v1.8.=
2.0
Influenza Updates:
- Added CVX 186 to the Influenza Vaccines table.
8/1/2017: Release v1.8.=
1.0
Pneumococcal Updates:
- Combined vaccine groups Pneumococcal Conjugate (PCV) and Pneumococcal P=
olysaccharide (PPSV) into one vaccine group called "Pneumococcal Vaccine Gr=
oup".
Meningococcal ACWY Updates:
- Removed the following rules:
- If a patient's age at administration is >=3D 19 years and the p=
atient did NOT complete the series before 19 years of age, then the Ev=
aluation is Accepted and the reason code is ABOVE_REC_AGE.
- Shots administered to a patient >=3D 19 years of age do NOT count to=
ward completion of the series; the series can NOT be completed once the pat=
ient is >=3D 19 years old.
- And replaced with the following rules:
- Shots administered to a patient who is >=3D 19 years and < 22 yea=
rs of age will continue to be evaluated (based on minimum intervals) and, i=
f valid, will count toward completion of the series.
- If a patient's age at administration is >=3D 22 years and the patien=
t did NOT complete the series before 22 years of age, then the Evaluation i=
s Accepted and the reason code is ABOVE_REC_AGE_SERIES. (Shots administered=
to a patient >=3D 22 years of age do NOT count toward completion of the=
series; the series can NOT be completed once the patient is >=3D 2=
2 years old.)
- Updated CVX 108 Absolute Minimum Age from 9 months - 4 days to 2 years =
minus 4 days.
- Updated Absolute Minimum Age for Dose 1 of MCV4 2-dose series from 10 y=
ears minus 4 days to 10 years.
Polio Updates:
- Added CVX 170 to Polio Vaccines table.
- Removed the Series Complete with 5 doses rule
- Added rule - For children who received target dose 4 at >=3D 8/7/201=
0 and before 4 years - 4 days of age, evaluate target dose 4 as Accepted/ B=
ELOW_MINIMUM_AGE_FINAL_DOSE (if absolute minimum interval is met). (An addi=
tional dose will be recommended at >=3D 4 years of age).
- Added rule - OPV Rule - If a patient receives shots of OPV administered=
>=3D 4/1/2016, these shots do not count towards the series. Evaluate th=
ese shots as Invalid with reason code MISSING_ANTIGEN.
- Added 3 new OPV vaccines (CVX 178, 179, 182) to the Polio Vaccines tabl=
e.
- Added Rule for CVX 178 and CVX 179 - If a patient receives CVX 178 or C=
VX 179, evaluate these shots as Invalid with reason code MISSING_ANTIGEN.=
li>
- Updated the Series Complete with 3 doses rule to:
- If all administered doses are IPVs (containing component CVX 10) o=
r all administered doses are OPVs (containing component CVX 02 or CVX =
182), and dose 3 was administered when the patient was >=3D 4 =
years and was administered at least 6 months - 4 days after the previo=
us dose, then the series is complete with 3 doses.
Influenza Updates:
- Added CVX 185 to the Influenza Vaccines table.
2/27/2017: Release v1.=
7.1.0
Polio Updates:
- Modifications for 5-dose series: restriction that child be born >=3D=
1/1/2006 removed and 4th dose must be given before 8/7/2010 instead of 1/1=
/2010 to be recommended 5th dose.
- Change Cut-off date for Dose 4 Absolute Min Age/Min Age and Absolute Mi=
n Interval/Min Interval
12/1/2016: Release v1.=
6.1.0
HPV Updates:
- Added support for new 2-Dose Series; recommend according to 2- or=
3-dose series accordingly
- Ignore (HPV, bivalent (Cervarix)) shots administered to males
- Remove minimum/absolute minimum age restriction for dose 2 and do=
se 3
Meningococcal ACWY Updates:
- Add absolute minimum age/minimum age of 16 years for Dose 2 =
- Change recommended interval between Dose 1 and Dose 2 from 3 year=
s to 56 days
9/23/2016: Release v1.=
4.1.0
Zoster Updates:
Influenza Updates:
- Added rule to mark vaccine CVX 161 Invalid due to Insufficient Antigen =
if patient >=3D 3yrs
Meningococcal B Updates:
- Until supported by ICE, mark administration of Meningococcal B vaccines=
as "not supported" and include in "Other" vaccine group category of foreca=
st. (The ICE team is working on support for Meningococcal B in a futu=
re release.)
8/15/2016: Release v1.=
3.1.2
Influenza Updates:
- Influenza 2016-2017 season: added influenza vaccines CVX 168 and CVX 17=
1
8/12/2016: Release v1.=
3.1.0
Hep A Updates:
- Hep A logic updates. To better accommodate twinrix, ICE is adding a sec=
ond series selection rule for the Hep A 3-dose series. Please refer to the =
wiki for the most up-to-date documentation of the rules.
Meningococcal Updates:
- Meningococcal: Fixed a bug whereby in rare cases ICE recommends a 2nd d=
ose when the series is complete was complete with 1-dose.
Other Updates:
- Support for ICD-10 and SNOMED-CT codes. Previous releases accepted ICD-=
9 diagnosis codes when reporting evidence of immunity (history of disease o=
r serology). With this new enhancement, ICD-10 and SNOMED-CT codes are also=
accepted. Refer to the ICE Client Implementation Guide for details.
------=_Part_20_1460884285.1711642627071--